Trials / Terminated
TerminatedNCT05848219
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 543 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of Benefit. We conducted this analysis using the most recent available data from the MarketScan database at the time of analysis, which was 01 June 2018 to 31 December 2020. We initiated this analysis from 01 June 2018 as encorafenib + binimetinib (enco/bini) was approved for patients with unresectable or metastatic melanoma with BRAF mutation at this time.
Conditions
Timeline
- Start date
- 2021-10-16
- Primary completion
- 2022-04-27
- Completion
- 2022-04-27
- First posted
- 2023-05-08
- Last updated
- 2023-05-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05848219. Inclusion in this directory is not an endorsement.